There is no question that effective & safe vaccines will offer the best solution for preventing GBS. We are at a really exciting point in vaccine development with several GBS vaccines now in trials involving pregnant women. What are these vaccines? How will they be licensed? What have we learned from other vaccines about how best to implement and then assess them? What impact will they have? These are among the important questions the experts in session 4 will address!
|Conveners: Prof. Paul Heath & Dr. Clare Cutland|
|S1: Prof. Paul Heath (15 min) |
Title: Vaccine Science Overview
|S2: Dr. Pauline Paterson (15 min) |
Title: What have we learned about vaccine confidence in pregnant women?
|S3: Dr. Ajoke Sobanjo Ter Meulen (15 min) |
Title: What is the likely impact of an effective GBS vaccine on AMR?
|S4: Per Fischer (5 min)|
Title: Development of protein-only GBS vaccine based on N- terminal domains of the GBS Alpha-protein family
|S5: Penda Johm (5 min)|
Title: Acceptance of new maternal vaccines by women in The Gambia – a qualitative exploration
|Panel Discussion (25 min)|
|S6: Dr. Morena Makhoana|
|S7: Prof. Shabir Madhi|
|S8: Dr. Pauline Paterson|
|Closing Comments: Prof. Paul Heath & Dr. Clare Cutland|